Virax Biolabs Group Limited Ordinary Shares (VRAX) — Financial Flexibility Index

Latest as of September 2025: -4.34x

Virax Biolabs Group Limited Ordinary Shares (VRAX) has a Financial Flexibility Index of -4.34x as of September 2025. Free cash flow of $-2.78 Million (operating CF $-2.92 Million minus capex $141.50K) represents -4% of total liabilities ($641.52K). Check Virax Biolabs Group Limited Ordinary Sha (VRAX) asset resilience to evaluate the company's liquid asset resilience ratio.

Financial Flexibility Index

-4.34x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-2.78 Million
Operating CF − Capex

Total Liabilities

$641.52K
USD

Capital Expenditures

$141.50K
USD

Virax Biolabs Group Limited Ordinary Shares Financial Flexibility Index (2020–2025)

Historical Financial Flexibility Index trend for Virax Biolabs Group Limited Ordinary Shares across 6 annual periods. See Virax Biolabs Group Limited Ordinary Sha (VRAX) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for Virax Biolabs Group Limited Ordinary Shares (2020–2025)

Year-by-year free cash flow to debt coverage for Virax Biolabs Group Limited Ordinary Shares. For the full company profile including market capitalisation, see VRAX company net worth.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -4.10x $-3.96 Million $-4.56 Million $964.75K ▲ +72.1%
2024 -14.72x $-5.08 Million $-6.25 Million $345.19K ▼ -234.3%
2023 -4.40x $-4.00 Million $-4.18 Million $908.40K ▼ -578.0%
2022 -0.65x $-809.07K $-809.07K $1.25 Million ▲ +4.1%
2021 -0.68x $-590.19K $-590.19K $871.43K ▼ -12.6%
2020 -0.60x $-744.61K $-744.61K $1.24 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities